Suggestions

Du même auteur

SGLT2 inhibition by empagliflozin attenuates ectopic fat accumulation and improves cardiac index in parallel to ketone bodies production: the EMPAFAT study

Archive ouverte | Maurice, F. | CCSD

WOS:000408315003010. International audience

Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study

Archive ouverte | Gaborit, B. | CCSD

International audience. Abstract Background Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that has demonstrated cardiovascular and renal protection in patients with type 2 diabetes (T2D). We hy...

Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy.

Archive ouverte | Dutour, A. | CCSD

International audience. AIM: To conduct a prospective randomized trial to investigate the effect of glucagon-like peptide-1 (GLP-1) analogues on ectopic fat stores. METHODS: A total of 44 obese subjects with type 2 ...

Chargement des enrichissements...